Company intelligence / Profile preview

Avida Biomed

Santa Clara, California, United States

Ownership: Private
Development stage: Other

Overview

Avida Biomed developed a novel target enrichment workflow (Point-n-Seq) enabling simultaneous genomic and methylation profiling from single samples, validated for liquid biopsy use; now part of Agilent’s SureSelect portfolio, supporting clinical research in cancer, diagnosis, and biomarker discovery

Therapeutic areas: Oncology
Modalities: Diagnostic testNGS target enrichment technologyLiquid biopsy platform
Industry: Molecular Diagnostics

Partnerships

Agilent Technologies (acquisition/technology integration)

Beyond the preview

Go deeper on Avida Biomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avida Biomed.

Explore the full profile